As of Wednesday close, Citius Pharmaceuticals Inc.’s (NASDAQ:CTXR) stock was up $0.02, moving up 1.75 percent to $1.16. The average number of shares traded per day over the past five days has been 575,260 shares. 3 times new highs have been achieved over the past 5 days, with a $0.0600 gain in that time frame. In the last twenty days, the average volume was 482,665, while in the previous 50 days, it was 494,094.
Since last month, CTXR stock rose 8.41%. Shares of the company fell to $1.0100 on 11/04/22, the lowest level in the past month. A 52-week high of $2.01 was reached on 04/06/22 after having rallying from a 52-week low of $0.83. Since the beginning of this year, CTXR’s stock price has dropped by -24.68% or -$0.3800, and marked a new high 8 times. However, the stock has declined by -42.29% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
In the three months ended June 29, Citius Pharmaceuticals Inc.’s quick ratio stood at 11.40, while its current ratio was 11.40, showing that the company is able to pay off its debt. Based on annual data, CTXR earned $11000.0 in gross profit and brought in $23.53 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Citius Pharmaceuticals Inc. to report -$0.05 quarterly earnings, the actual figure was -$0.06 per share. During the quarter, the company generated -$8.87 million in EBITDA. The liabilities of Citius Pharmaceuticals Inc. were 9.98 million at the end of its most recent quarter ended June 29, and its total debt was $0.72 million. The value of shareholders’ equity is $146.13 million.
This quick technical analysis looks at Citius Pharmaceuticals Inc.’s (CTXR) price momentum. With a historical volatility rate of 40.90%, the RSI 9-day stood at 64.05% on 23 November.
With respect to its five-day moving average, the current Citius Pharmaceuticals Inc. price is up by +5.45% percent or $0.0600. At present, CTXR shares trade +10.48% above its 20-day simple moving average and +29.81% percent above its 100-day simple moving average. However, the stock is currently trading approximately -5.69% below its SMA50 and -20.55% below its SMA200.
Stochastic coefficient K was 77.78% and Stochastic coefficient D was 77.25%, while ATR was 0.0591. Given the Stochastic reading of 71.43% for the 14-day period, the RSI (14) reading has been calculated as 58.41%. As of today, the MACD Oscillator reading stands at 0.0378, while the 14-day reading stands at 0.0640.
Maxim Group launched its rating on Citius Pharmaceuticals Inc. (NASDAQ: CTXR) to a Buy in a note to investors on November 30, 2021. Citius Pharmaceuticals Inc. (CTXR) has been rated Buy by analysts. According to 0 brokerage firms, CTXR is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Citius Pharmaceuticals Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $7.00, the current consensus forecast for the stock is $4.00 – $10.00. Based on these forecasts, analysts predict Citius Pharmaceuticals Inc. (CTXR) will achieve an average price target of $7.00.